Display options
Cite
Taniguchi H, Tsuchida T, Nakamura Y, et al. Severe, but manageable hypoxia caused by bronchospasm induced by bevacizumab. Respirol Case Rep. 2013;1(1):14-6doi: 10.1002/rcr2.10.
Taniguchi, H., Tsuchida, T., Nakamura, Y., Motoshima, K., Mizoguchi, K., & Kohno, S. (2013). Severe, but manageable hypoxia caused by bronchospasm induced by bevacizumab. Respirology case reports, 1(1), 14-6. https://doi.org/10.1002/rcr2.10
Taniguchi, Hirokazu, et al. "Severe, but manageable hypoxia caused by bronchospasm induced by bevacizumab." Respirology case reports vol. 1,1 (2013): 14-6. doi: https://doi.org/10.1002/rcr2.10
Taniguchi H, Tsuchida T, Nakamura Y, Motoshima K, Mizoguchi K, Kohno S. Severe, but manageable hypoxia caused by bronchospasm induced by bevacizumab. Respirol Case Rep. 2013 Sep;1(1):14-6. doi: 10.1002/rcr2.10. Epub 2013 Aug 29. PMID: 25473529; PMCID: PMC4184640.
Copy Download .nbib Format: NLM
Share it on

Respirol Case Rep. 2013 Sep;1(1):14-6. doi: 10.1002/rcr2.10. Epub 2013 Aug 29.

Severe, but manageable hypoxia caused by bronchospasm induced by bevacizumab.

Respirology case reports

Hirokazu Taniguchi, Tomoko Tsuchida, Yoichi Nakamura, Kohei Motoshima, Kosuke Mizoguchi, Shigeru Kohno

Affiliations

  1. Second Department of Internal Medicine, Nagasaki University School of Medicine Nagasaki, Japan ; Sasebo City General Hospital Sasebo, Japan.
  2. Second Department of Internal Medicine, Nagasaki University School of Medicine Nagasaki, Japan.

PMID: 25473529 PMCID: PMC4184640 DOI: 10.1002/rcr2.10

Abstract

Bevacizumab has a lower risk of treatment-related infusion reactions than other humanized monoclonal antibodies, and bronchospasm induced by bevacizumab has not been reported. We administered bevacizumab 15 mg/kg over 90 min infusion to a 34 year-old man with lung adenocarcinoma and childhood asthma. Then, grade 3 hypoxia developed and improved spontaneously. This reversible obstructive lung disorder was confirmed using a flow-volume loop, and the patient was diagnosed as having a bronchospasm due to infusion reaction of bevacizumab. This bronchospasm was easily manageable and preventable using an oral bronchodilator and an inhalant combination product, and the patient continued with bevacizumab therapy until the disease progression.

Keywords: bevacizumab; bronchospasm; infusion reaction; non-small cell lung cancer

References

  1. Oncologist. 2008 Jun;13(6):725-32 - PubMed
  2. Oncologist. 2007 May;12(5):601-9 - PubMed
  3. Support Care Cancer. 2008 Apr;16(4):393-8 - PubMed
  4. Nature. 1993 Apr 29;362(6423):841-4 - PubMed
  5. Semin Oncol. 1992 Oct;19(5):458-77 - PubMed

Publication Types